Antimicrobial Peptide Engineering for Resistant Microbes

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The emergence of antimicrobial resistance has reduced the effectiveness of standard antimicrobial treatments, leading to a need for new therapeutics with broad-spectrum antimicrobial activity to inhibit the growth and spread of resistant microorganisms.

Innovation Solution

Development of synthetic antimicrobial peptides with specific amino acid sequences, such as those following the formula Gly-X1-X2-X3-X1-Arg-X4-X1-X5-X6-Gly, and their use in formulations that include linker sequences to enhance solubility and stability, targeting a wide range of microorganisms including bacteria, fungi, and viruses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If standard antimicrobial treatments are used, then treatment effectiveness is maintained against susceptible organisms, but effectiveness decreases against resistant organisms

Engineering Contradiction:
Improveantimicrobial treatment effectivenessVSAvoidbroad-spectrum activity against resistant organisms
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent modifies the natural defensin-1 peptide sequence by substituting specific amino acids (e.g., position 3 with hydrophobic residues, position 6 with charged residues, position 12 with aromatic residues) to optimize antimicrobial activity against resistant organisms while maintaining stability and solubility parameters

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates composite peptide structures by fusing defensin-1 with alpha-defensin sequences or linking multiple defensin-1 copies together, generating hybrid peptides with enhanced and broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative resistant bacteria

Inventive Principle:
Principle #40Composite materials

2Adaptability or versatility

If new antimicrobial therapies are developed to target resistant organisms, then broad-spectrum activity is achieved, but the number of approved therapies decreases

Engineering Contradiction:
Improvebroad-spectrum antimicrobial activityVSAvoidnumber of new antimicrobial therapies approved
Core Design Contradiction:
Adaptability or versatilityVSProductivity

Solution Approach 1:

The patent identifies and optimizes specific functional regions within the defensin-1 sequence (N-terminal region for membrane interaction, central region for stability, C-terminal region for antimicrobial activity), allowing systematic engineering of variants with improved properties while maintaining the core antimicrobial mechanism

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent applies targeted amino acid substitutions at specific positions to enhance particular properties: hydrophobic residues at position 3 for membrane penetration, charged residues at position 6 for solubility, and aromatic residues at position 12 for binding affinity, rather than random modifications

Inventive Principle:
Principle #3Local quality

3Reliability

If peptide sequences are optimized for antimicrobial activity, then efficacy against resistant organisms increases, but solubility and stability may be compromised

Engineering Contradiction:
Improveantimicrobial efficacyVSAvoidpeptide solubility and chemical stability
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent systematically adjusts amino acid properties at key positions to balance antimicrobial activity with solubility and stability: introducing charged residues (Asp, Glu, Lys, Arg) to enhance solubility, selecting residues with appropriate hydrophobicity for membrane interaction without aggregation, and incorporating proline or glycine to prevent unwanted beta-sheet formation and maintain peptide flexibility

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP3179855B1Water buffalo derived peptide antibiotic therapies
Publication Date: 2019.11.20 CENTAUR INC
  • EP3179855B1 patent drawingFigure 1
  • EP3179855B1 patent drawingFigure 2
  • EP3179855B1 patent drawingFigure 3

AI summary

The present disclosure relates to antimicrobial agents and methods of using such agents. The disclosure includes antimicrobial agents having broad spectrum antimicrobial activity, nucleic acids and amino acid sequences encoding such antimicrobial agents, as well as methods of using the antimicrobial agents. The antimicrobial agents of the disclosure may be used to reduce survival of a microbe, as an antimicrobial therapeutic, in microbial treatment protocols, and in research, as well as other uses related to reducing microbe survival. In addition, the disclosure also includes compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial agent.